Portal de investigación
INTERVENCIÓN FARMACÉUTICA PARA LA MEJORA DEL RIESGO CARDIOVASCULAR EN PACIENTES VIH EN TRATAMIENTO ANTIRRETROVIRAL ACTIVO. ESTUDIO INFAMERICA.
Datos básicos
- Código:
- SEF-VIH-2012-01
- Protocolo:
- SEF-VIH-2012-01
- EUDRACT:
- NCT:
- Centro:
- Dotación:
- Año de incio:
- Año de finalización:
- 2014
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
Resultados del Ensayo Clínico
[[Translated article]]Improving the Management and Follow-up of Atopic Dermatitis: A Delphi Process Report of Consensus Between Hospital Dermatologists and Pharmacists.
Herranz-Pinto P; (...); Tortajada Goitia B
Practice Guideline. 10.1016/j.ad.2023.07.008. 2023
[Translated article] Cybersecurity: a priority for pharmacy services in the age of artificial intelligence
Marin, Cayetano M. Hernandez, Monte-Boquet, Emilio, Andres, Jose Luis Poveda
Editorial Material. 10.1016/j.farma.2024.08.009. 2024
[Translated article] Checklist for the pharmaceutical care of patients with interstitial lung disease (CheckEPID): A Delphi-based consensus.
Calvin-Lamas, Marta; (...); Ventayol Bosch, Pere
Article. 10.1016/j.farma.2023.09.004. 2023
2022 update of the indicators for quality of care and pharmaceutical care for people living with human immunodeficiency virus.
Martin Conde MT; (...); Morillo-Verdugo, Ramon
Article. 10.1016/j.farma.2023.04.008. 2023
2022 update of the indicators for quality of care and pharmaceutical care for people living with human immunodeficiency virus.
Martin, Maria Teresa; (...); Morillo-Verdugo, Ramon
Article. 10.1016/j.farma.2023.01.007. 2023
A Qualitative Tool to Guide in the Interpretation of the Numerical Rating Scale for Pruritus Intensity in Patients with Atopic Dermatitis.
Figueras I; (...); Ortiz de Frutos FJ
Article. 10.2340/actadv.v104.18255. 2024
Administration of Subcutaneous Furosemide in Elastomeric Pump vs. Oral Solution for the Treatment of Diuretic Refractory Congestion.
Lopez-Vilella, Raquel; (...); Almenar Bonet, Luis
Article. 10.1007/s40292-021-00476-4. 2021
Analisis de las causas de suspension de tratamiento con triple terapia antiviral en pacientes con hepatitis C.
Ruiz Ramos J; (...); Poveda Andrés JL
Abstract of Published Item. 10.7399/fh.2014.38.3.1171. 2014
Analysis of the situation of pharmaceutical care for patients with immune-mediated inflammatory diseases before and after the COVID-19 pandemic.
Lopez Sanchez, Piedad; (...); Monte Boquet, Emilio
Article. 10.1016/j.farma.2024.10.001. 2024
ANALYSIS OF THE USE OF MOBILE APPLICATIONS IN PATIENTS WITH HAEMOPHILIA AFTER TWO YEARS OF FOLLOW-UP
Megias Vericat, J. E.; (...); Bonanad Boix, S.
Meeting Abstract. 2019
Anidulafungin-Induced Alopecia
Ruiz-Ramos J; (...); Poveda-Andrés JL
Article. 10.1177/1060028014524534. 2014
Bayesian pharmacokinetic individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A
Megias-Vericat, JE; (...); Bonanad, S
Meeting Abstract. 2018
Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2018.12.027. 2019
BIOSIMILARS IMPACT ON THE RHEUMATOID ARTHRITIS TREATMENT: A COST-EFFECTIVENESS MODEL FROM SPANISH NATIONAL HEALTHCARE SYSTEM PERSPECTIVE
Fernandez Santos, J. M.; (...); Borras Blasco, J.
Meeting Abstract. 2022
Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2021.07.009. 2021
Clinical experiences with cannabinoids in spasticity management in multiple sclerosis
Lorente Fernández L; (...); Casanova-Estruch B
Article. 10.1016/j.nrl.2013.06.014. 2014
CLINICAL VALIDATION OF THE SPECIFIC POPULATION MODEL OF FACTOR VIII/FVW PLASMA USING WAPPS-HEMO
Megias Vericat, J. E.; (...); Poveda, A. J. L.
Meeting Abstract. 2019
Collaborative model of home delivery program in haemophilia through an association of patients
Megias-Vericat, JE; (...); Bonanad, S
Meeting Abstract. 2018
Comparison of pharmacokinetic estimates using generic and specific population pharmacokinetic models of plasma-derived factor VIII/VWF using WAPPS-Hemo
Megias-Vericat, JE; (...); Poveda, JL
Meeting Abstract. 2020
Consensus statement on the use of biosimilar drugs in immune-mediated diseases in Spain
Monte-Boquet, Emilio; (...); Sellas, Agusti
Article. 10.1016/j.reuma.2022.12.001. 2023
Cost analysis of biologic drugs in rheumatoid arthritis first line treatment aftermethotrexate failure according to patients' body weight
Roman Ivorra JA; (...); Gomez-Barrera M
Article. 10.1016/j.reuma.2015.07.008. 2016
COST-EFFECTIVENESS ANALYSIS OF BIOSIMILARS BASED TREATMENT SEQUENCES FOR MODERATE-TO-SEVERE CROHN DISEASE IN SPAIN
Fernandez Santos, J. M.; (...); Merino-Bohorquez, V
Meeting Abstract. 2022
Cost-effectiveness of methoxy polyethylene glycolepoetin beta versus conventional epoetin in the treatment of anaemia secondary to chronic kidney disease in clinical practice
Lorente-Fernandez, L; (...); Poveda-Andres, JL
Article. 10.1136/ejhpharm-2013-000426. 2015
Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate (R)) and BAY 81-8973 (KovaltryA (R)) in patients with severe or moderate haemophilia A in prophylaxis
Megias-Vericat, JE; (...); Poveda, JL
Letter. 10.1111/hae.13733. 2019
Cybersecurity, a priority for pharmacy services in the age of artificial intelligence.
Hernández Marín CM, Monte-Boquet E, Poveda Andrés JL
Editorial Material. 10.1016/j.farma.2024.08.001. 2024
Checklist for Pharmaceutical Care of the Patient with interstitial lung disease (CheckEPID): A Delphi-based consensus.
Calvin Lamas M; (...); Ventayol Bosch P
Article. 10.1016/j.farma.2023.06.010. 2023
Development and testing of a mobile app for systematic collection of patient-reported outcomes (PROs) in patients with hemophilia.
Megias-Vericat, J E; (...); Poveda Andres, J L
Letter. 10.1016/j.thromres.2024.109122. 2024
Elevating the Standard of Care for Patients with Psoriatic Arthritis: 'Calls to Action' from a Multistakeholder Pan-European Initiative.
Verbinnen I; (...); Helliwell PS
Article. 10.1007/s40744-024-00664-3. 2024
Experience of Home Delivery Program in Haemophilia Through an Association of Patients
Megias Vericat, J. E.; (...); Bonanad Boix, S.
Meeting Abstract. 2017
Expert consensus on the persistence of biological treatments in moderate-to-severe psoriasis
Dobao, PD; (...); Puig, L
Article. 10.1111/jdv.15600. 2019
Hereditary angioedema in Spain: medical care and patient journey.
Caballero, Teresa; (...); Zamora, Carolina
Article. 10.1186/s13023-024-03182-1. 2024
Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart (R) in patients with multiple sclerosis
Edo Solsona MD; (...); Poveda Andrés JL
Article. 10.2147/PPA.S127508. 2017
IMPACT OF ADHERENCE ON SUBCUTANEOUS INTERFERON BETA-1A EFFECTIVENESS ADMINISTERED BY REBISMART (R) IN PATIENTS WITH MULTIPLE SCLEROSIS
Edo-Solsona, M.; (...); Poveda-Andres, J.
Meeting Abstract. 10.1016/j.jval.2016.09.512. 2016
Importance of adherence to treatment with direct-acting antivirals in hepatitis C.
Monte-Boquet E; (...); Ventayol P
Article. 10.1016/S0210-5705(20)30183-7. 2019
Improving the Management and Follow-up of Atopic Dermatitis: A Delphi Process Report of Consensus Between Hospital Dermatologists and Pharmacists.
Herranz-Pinto P; (...); Tortajada Goitia B
Practice Guideline. 10.1016/j.ad.2023.04.019. 2023
Individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A
Vericat, JEM; (...); Bonanad, S
Meeting Abstract. 2018
Individualized Prophylactic Treatment with Recombinant Factor VIII in Severe or Moderate Haemophilia a Patients. Association Between Pharmacokinetic Parameters and Clinical Variables
Megias-Vericat, Juan Eduardo; (...); Bonanad, Santiago
Meeting Abstract. 10.1182/blood.V128.22.3802.3802. 2016
Inhaled aztreonam lysine in the management of Pseudomonas aeruginosa in patients with cystic fibrosis: real-life effectiveness.
Jimenez-Lozano, Ines; (...); Alvarez-Fernandez, Antonio
Article. 10.1136/ejhpharm-2023-003937. 2023
Knowledge, perceptions, attitude, barriers and facilitators of biosimilars use across specialty physicians and hospital pharmacists: A national survey
Marin-Jimenez, I; (...); Monte-Boquet, E
Article. 10.7399/fh.11662. 2021
Knowledge, perceptions, attitude, barriers and facilitators of biosimilars use across specialty physicians and hospital pharmacists: A national survey.
Marín-Jiménez I; (...); Monte-Boquet E
Article. 10.7399/fh.11662. 2021
National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies
Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis
Meeting Abstract. 10.1182/blood-2022-169938. 2022
Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus
Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis
Article. 10.1097/MD.0000000000032208. 2022
Oral Ribavirin for Treatment of Respiratory Syncytial Virus in Lung Transplantation Recipients.
Martin-Cerezuela, Maria; (...); Poveda-Andres, Jose Luis
Article. 10.1016/j.transproceed.2021.08.037. 2021
Patient-reported outcome measures in severe asthma: an expert consensus.
Martínez-Moragón E; (...); Sánchez-Cuellar S
Article. 10.1080/02770903.2023.2297372. 2023
Pharmaceutical care to hospital outpatients during the COVID-19 pandemic. Telepharmacy
Margusino-Framiñán L; (...); Morillo-Verdugo R
Article. 10.7399/fh.11498. 2020
Pilot evaluation of home delivery programme in haemophilia
Megias-Vericat, JE; (...); Poveda-Andres, JL
Article. 10.1111/jcpt.12718. 2018
PRELIMINAR STUDY OF THERAPY ADHERENCE CONTROLLED BY PRESCRIPTION OF MEDICATION AND SELF-PERCEPTION ADHERENCE OF INFLAMMATORY CHRONIC DISEASE PATIENTS
Garcia, EG; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2019-eular.5937. 2019
Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice
Aguas Peris M; (...); Nos, P
Article. 10.1097/MIB.0000000000001182. 2017
Serum adalimumab levels predict successful remission and safe de-intensification in inflammatory bowel disease patients in clinical practice
Meeting Abstract. 2017
Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis
González-Álvaro I; (...); Spanish Rheumatology Society
Article. 10.1093/rheumatology/keu461. 2015
Spanish Society of Hospital Pharmacy Position Statement on Telepharmacy: Recommendations for its implementation and development
Morillo-Verdugo, R; (...); Delgado-Sanchez, O
Article. 10.7399/fh.11515. 2020
Study on the Linezolid Prescription According to the Approval of Indication in a University Hospital
Pérez-Cebrián M; (...); Llopis-González A
Article. 2015
Telematic Interview in Telepharmacy: a comprehensive guide for pharmacotherapeutic follow-up and and informed drug delivery.
Barbadillo-Villanueva S; (...); Monte-Boquet E
Article. 10.1016/j.farma.2024.04.008. 2024
Telematic interview in telepharmacy: consensus document for farmacotherapeutic monitoring and informed drug delivery.
Barbadillo-Villanueva S; (...); Monte-Boquet E
Article. 10.1016/j.farma.2024.01.006. 2024
TELEPROM Psoriasis: Enhancing patient-centered care and health-related quality of life (HRQoL) in moderate-to-severe plaque psoriasis.
Mercadal-Orfila G; (...); Herrera-Pérez S
Article. 10.3389/fmed.2024.1465725. 2024
Treatment Persistence and Safety of Apremilast in Psoriasis: Experience With 30 Patients in Routine Clinical Practice
Sahuquillo-Torralba, A; (...); Estrada, RB
Article. 10.1016/j.ad.2018.10.031. 2020